We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Test Identifies Resistance Mutation that Enables Use of Inexpensive, Single Dose Gonorrhea Drug

By LabMedica International staff writers
Posted on 17 Aug 2020
By detecting the mutated gene responsible for resistance to the drug ciprofloxacin, it is possible to identify gonorrhea patients who can be cured by a single oral dose of this drug.

Gonorrhea, a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, remains a major public health issue worldwide with the World Health Organization (WHO) estimating that 87 million new cases of gonorrhea occur annually. More...
Untreated gonorrhea contributes to serious reproductive and sexual health problems, including pelvic inflammatory disease, infertility, and an increased risk of transmission of human immunodeficiency virus (HIV).

Use of the inexpensive oral antibiotic ciprofloxacin to treat gonorrhea has largely been discontinued over concerns that the bacterium was becoming resistant to it. On the other hand, a molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections.

Investigators at the University of California, Los Angeles (USA) used this genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon. They then conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure five to 10 days post-treatment.

Results showed that of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment was 100%. Thus, oral ciprofloxacin was highly effective against infections caused by the bacterium lacking the gyrA serine mutation.

"The new test gives doctors more choices to treat the sexually transmitted infection and could help slow down the spread of drug-resistant gonorrhea," said first author Dr. Jeffrey Klausner, professor of medicine at the University of California, Los Angeles. "Gonorrhea is one of the most common drug-resistant infections worldwide and is becoming harder to treat. Current treatment methods require an antibiotic injection, which is expensive and painful. This new test could make it easier and safer to treat gonorrhea with different antibiotics, including one pill given by mouth. Using a pill instead of a shot would also make it easier and faster to treat sex partners of patients with gonorrhea."

The paper was published in the August 7, 2020, online edition of the journal Clinical Infectious Diseases.

Related Links:

University of California, Los Angeles


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.